Literature DB >> 20156929

Peripheral neuropathy in patients with primary antiphospholipid (Hughes') syndrome.

M S F Santos1, J F de Carvalho, M Brotto, E Bonfa, F A C Rocha.   

Abstract

The involvement of the peripheral nervous system in diverse autoimmune diseases is well established. However, no appropriately designed studies have been performed in primary antiphospholipid syndrome (PAPS)-related peripheral neuropathy. We aimed to investigate the occurrence of peripheral neuropathy in patients diagnosed with PAPS. Twenty-six consecutive patients with PAPS (Sapporo criteria) and 20 age- and gender-matched healthy controls were enrolled at two referral centers. Exclusion criteria were secondary causes of peripheral neuropathy. A complete clinical neurologic exam followed by nerve conduction studies (NCS) was performed. Paresthesias were reported in eight patients (31%). Objective mild distal weakness and abnormal symmetric deep tendon reflexes were observed in three patients (11.5%). With regard to the electrophysiologic evidence of peripheral neuropathy, nine patients (35.0%) had alterations: four (15.5%) had pure sensory or sensorimotor distal axonal neuropathy (in two of them a carpal tunnel syndrome was also present) and one (4%) had sensorimotor demyelinating and axonal neuropathy involving upper and lower extremities, while four patients (15.5%) showed isolated carpal tunnel syndrome. Clinical and serologic results were similar in all the patients with PAPS, regardless of the presence of electrophysiologic alterations. In conclusion, peripheral neuropathy is a common asymptomatic abnormality in patients with PAPS. The routine performance of NCS may be considered when evaluating such patients.

Entities:  

Mesh:

Year:  2010        PMID: 20156929     DOI: 10.1177/0961203309354541

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

1.  Chorea in primary antiphospholipid syndrome is associated with rheumatic fever.

Authors:  Simone Appenzeller; Steeven Yeh; Marcelo Maruyama; Solange Murta Barros; Jozélio Freire de Carvalho
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

2.  Antiphospholipid Syndrome: A complex disease.

Authors:  Fátima Serrano
Journal:  J Nephropathol       Date:  2013-01-01

3.  Antiphospholipid syndrome: A disease of protean face.

Authors:  Mohammadreza Ardalan; Amir Vahedi
Journal:  J Nephropathol       Date:  2013-01-01

4.  Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.

Authors:  Elodie Rivière; Fleur Cohen Aubart; Thierry Maisonobe; François Maurier; Christophe Richez; Bruno Gombert; Marie Gousseff; Daniel Adoue; Alexis Mathian; Miguel Hié; Julien Haroche; Zahir Amoura
Journal:  J Neurol       Date:  2017-05-23       Impact factor: 4.849

Review 5.  Neurologic Manifestations of Catastrophic Antiphospholipid Syndrome.

Authors:  Rafid Mustafa
Journal:  Curr Neurol Neurosci Rep       Date:  2022-08-30       Impact factor: 6.030

Review 6.  Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy.

Authors:  Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

Review 7.  Immune Axonal Neuropathies Associated With Systemic Autoimmune Rheumatic Diseases.

Authors:  Delia Tulbă; Bogdan Ovidiu Popescu; Emilia Manole; Cristian Băicuș
Journal:  Front Pharmacol       Date:  2021-04-14       Impact factor: 5.810

Review 8.  Role of Demyelination in the Persistence of Neurological and Mental Impairments after COVID-19.

Authors:  Marina Y Khodanovich; Daria A Kamaeva; Anna V Naumova
Journal:  Int J Mol Sci       Date:  2022-09-25       Impact factor: 6.208

Review 9.  Neurologic Manifestations of the Antiphospholipid Syndrome - an Update.

Authors:  Miguel Leal Rato; Matilde Bandeira; Vasco C Romão; Diana Aguiar de Sousa
Journal:  Curr Neurol Neurosci Rep       Date:  2021-06-14       Impact factor: 5.081

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.